Recent Updates
Recently added Catalysts

BNT326

Phase 1

Advanced Solid Tumor | Small molecule | Oncology |BioNTech SE|Last Updated: Sep 2, 2026

Target and mechanism

Molecular targetHER3
Target classProtein
ModalitySmall molecule

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedCONTROLLED
Total Trials1
Total Enrollment1,438

FDA Designations

No designations recorded

Clinical trial landscape

BNT326 · 2 trials · 2 indications

Phase 1 2
NCT07111520A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)Non-small Cell Lung Cancer
RECRUITING880 Analytics
NCT07070232A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant TumorsAdvanced Solid Tumor
RECRUITING1,438 Analytics
PHASE1RECRUITING
A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
Non-small Cell Lung CancerUnlock trial analytics
PHASE1RECRUITING
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
Advanced Solid TumorUnlock trial analytics

Study Endpoints

Primary Endpoints

Part 1 - Occurrence of dose limiting toxicities (DLTs) within a participant
21 days starting on Day 1 of Cycle 1

During the DLT evaluation period by dose level

Part 1 and Part 2a - Occurrence of treatment emergent adverse events (TEAEs), treatment-related adverse events (TRAE), treatment emergent serious adverse events (TESAE), treatment-related serious adverse events (TRSAE)
from the first dose of investigational medicinal product (IMP) up to 90 days after the last dose of IMP or until a new systemic anti-cancer therapy is started, whichever occurs first (up to a maximum of 27 months)
Part 1 and Part 2a - Occurrence of dose interruption, reduction, and discontinuation due to TEAEs
from the first dose of IMP up to 90 days after the last dose of IMP or until a new systemic anti-cancer therapy is started, whichever occurs first (up to a maximum of 27 months)
Part 2a and Part 2b - Objective response rate (ORR)
from the time of initiation of the first dose of IMP to approximately 36 months

Defined as the percentage of participants in whom a confirmed complete response (CR) or partial response (PR) (per Response Evaluation Criteria in Solid Tumors version 1.1 \[RECIST v1.1\] based on the investigator's assessment) is observed as best overall response.

Parts 1 and 2 - All cohorts except Cohort 1F - Occurrence of treatment emergent adverse events (TEAEs), treatment related adverse events (TRAEs), treatment emergent serious adverse events (TESAEs), and treatment related serious adverse events (TRSAEs)
from first dose of investigational medicinal product (IMP) up to 42 days (Part 1) and 90 days (Part 2) after the last dose of IMP or until a new systemic anti-cancer therapy is started, whichever occurs first (up to 26 months Part 1 or 27 months Part 2)

By cohort and by dose in (Part 1), and by cohort and combination treatment regimen (in Part 2).

Parts 1 and 2 - All cohorts except Cohort 1F - Occurrence of dose interruption, reduction, and treatment discontinuations due to TEAEs
from first dose of IMP up to 42 days (Part 1) and 90 days (Part 2) after the last dose of IMP or until a new systemic anti-cancer therapy is started, whichever occurs first (up to 26 months Part 1 or 27 months Part 2)

By cohort and by dose in (Part 1), and by cohort and combination treatment regimen (in Part 2)

Parts 1 and 2 - All cohorts except Cohort 1F - Confirmed overall response rate (ORR)
from the time of initiation of the first dose of IMP up to approximately 38 months (Part 1) and approximately 48 months (Part 2)

Defined as the proportion of participants in whom a confirmed complete response (CR) or partial response (PR) based on the investigator's assessment (per Response Evaluation Criteria in Solid Tumors version 1.1 \[RECIST v1.1\]) is observed as best overall response. By cohort and by dose in (Part 1), and by cohort and combination treatment regimen (in Part 2).

Part 2 - Occurrence of dose limiting toxicities (DLTs)
from the time of initiation of the first dose of IMP up to 21 days

During the DLT observation period.

Part 1 - Cohort 1F (DDI) only - PK assessment: Maximum concentration (Cmax) derived from serum concentrations of BNT326 ADC and unconjugated payload
from the time of initiation of the first dose of IMP up to safety follow-up visit, approximately 42 days post last IMP dose

Evaluation of Cmax without and in combination with the CYP inhibitors (± itraconazole or ± paroxetine). Treatment comparison using geometric mean ratio of Cycle 3 as compared with Cycle 2 as a reference.

Part 1 - Cohort 1F (DDI) only - PK assessment: Area under the curve (AUC) over the last 17-day dosing interval derived from serum concentrations of BNT326 ADC and unconjugated payload
from the time of initiation of the first dose of IMP up to safety follow-up visit, approximately 42 days post last IMP dose

Evaluation of AUC over the last 17-day dosing interval without and in combination with the CYP inhibitors (± itraconazole or ± paroxetine). Treatment comparison using geometric mean ratio of Cycle 3 as compared with Cycle 2 as a reference.

Secondary Endpoints

Part 1 - ORR
from the time of initiation of the first dose of IMP to approximately 36 months
Part 2b - Occurrence of TEAEs, TRAEs, TESAEs, TRSAEs
from the first dose of IMP up to 90 days after the last dose of IMP or until a new systemic anti-cancer therapy is started, whichever occurs first (up to a maximum of 27 months)
Part 2b - Occurrence of dose interruption, reduction, and discontinuation due to TEAEs
from the first dose of IMP up to 90 days after the last dose of IMP or until a new systemic anti-cancer therapy is started, whichever occurs first (up to a maximum of 27 months)
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingNONE
ModelSEQUENTIAL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Part 1 - BNT326 (DL1) + pumitamig (DL1)EXPERIMENTALCombination therapy of BNT326 and pumitamig, starting dose. In participants with second-line (or higher) 2L(+), squamous or non-squamous NSCLC, actionable genomic alterations (AGA)-negative/positive, any programmed death-ligand 1 (PD-L1).
Part 1 - BNT326 (DL2) + pumitamig (DL1)EXPERIMENTALCombination therapy of BNT326 and pumitamig. In participants with 2L(+), squamous or non-squamous NSCLC, AGA-negative/positive, any PD-L1.
Part 1 - BNT326 (DL3) + pumitamig (DL1)EXPERIMENTALCombination therapy of BNT326 and pumitamig. In participants with 2L(+), squamous or non-squamous NSCLC, AGA-negative/positive, any PD-L1.
Part 1 - BNT326 (DL1) + pumitamig (DL2)EXPERIMENTALCombination therapy of BNT326 and pumitamig. In participants with 2L(+), squamous or non-squamous NSCLC, AGA-negative/positive, any PD-L1.
Part 1 - BNT326 (DL2) + pumitamig (DL2)EXPERIMENTALCombination therapy of BNT326 and pumitamig. In participants with 2L(+), squamous or non-squamous NSCLC, AGA-negative/positive, any PD-L1.
Part 1 - BNT326 (DL3) + pumitamig (DL2)EXPERIMENTALCombination therapy of BNT326 and pumitamig. In participants with 2L(+), squamous or non-squamous NSCLC, AGA-negative/positive, any PD-L1.
Part 2a (Cohort A, Arm 1) - BNT326 (DL1) + pumitamig (DL1)EXPERIMENTALCombination therapy of BNT326 and pumitamig. In participants with 2L+ squamous or non-squamous NSCLC, AGA-negative/positive, any PD-L1.
Part 2a (Cohort A, Arm 2) - BNT326 (DL2) + pumitamig (DL1)EXPERIMENTALCombination therapy of BNT326 and pumitamig. In participants with 2L+ squamous or non-squamous NSCLC, AGA-negative/positive, any PD-L1.
Part 2a (Cohort A, Arm 3) - BNT326 (DL3) + pumitamig (DL1)EXPERIMENTALCombination therapy of BNT326 and pumitamig. In participants with 2L+ squamous or non-squamous NSCLC, AGA-negative/positive, any PD-L1.
Part 2a (Cohort A, Arm 4) - BNT326 (DL1) + pumitamig (DL2)EXPERIMENTALCombination therapy of BNT326 and pumitamig. In participants with 2L+ squamous or non-squamous NSCLC, AGA-negative/positive, any PD-L1.
Part 2a (Cohort A, Arm 5) - BNT326 (DL2) + pumitamig (DL2)EXPERIMENTALCombination therapy of BNT326 and pumitamig. In participants with 2L+ squamous or non-squamous NSCLC, AGA-negative/positive, any PD-L1.
Part 2a (Cohort A, Arm 6) - BNT326 (DL3) + pumitamig (DL2)EXPERIMENTALCombination therapy of BNT326 and pumitamig. In participants with 2L+ squamous or non-squamous NSCLC, AGA-negative/positive, any PD-L1.
Part 2a (Cohort B, Arm 1) - BNT326 (DL1) + pumitamig (DL1)EXPERIMENTALCombination therapy of BNT326 and pumitamig. In participants with first-line (1L) squamous or non-squamous NSCLC, AGA-negative, any PD-L1.
Part 2a (Cohort B, Arm 2) - BNT326 (DL2) + pumitamig (DL1)EXPERIMENTALCombination therapy of BNT326 and pumitamig. In participants with 1L squamous or non-squamous NSCLC, AGA-negative, any PD-L1.
Part 2a (Cohort B, Arm 3) - BNT326 (DL3) + pumitamig (DL1)EXPERIMENTALCombination therapy of BNT326 and pumitamig. In participants with 1L squamous or non-squamous NSCLC, AGA-negative, any PD-L1.
Part 2a (Cohort B, Arm 4) - BNT326 (DL1) + pumitamig (DL2)EXPERIMENTALCombination therapy of BNT326 and pumitamig. In participants with 1L squamous or non-squamous NSCLC, AGA-negative, any PD-L1.
Part 2a (Cohort B, Arm 5) - BNT326 (DL2) + pumitamig (DL2)EXPERIMENTALCombination therapy of BNT326 and pumitamig. In participants with 1L squamous or non-squamous NSCLC, AGA-negative, any PD-L1.
Part 2a (Cohort B, Arm 6) - BNT326 (DL3) + pumitamig (DL2)EXPERIMENTALCombination therapy of BNT326 and pumitamig. In participants with 1L squamous or non-squamous NSCLC, AGA-negative, any PD-L1.
Part 2b (Cohort C, Arm 1) - BNT326 + pumitamigEXPERIMENTALCombination therapy of BNT326 and pumitamig. In participants with 2L+, squamous or non-squamous NSCLC, AGA-negative or epithelial growth factor receptor (EGFR) activating mutation, any PD-L1. DLs used will be determined by the IRC based on data generated from Part 1 and Part 2a.
Part 2b (Cohort C, Arm 2) - BNT326 + pumitamigEXPERIMENTALCombination therapy of BNT326 and pumitamig. In participants with 2L+, squamous or non-squamous NSCLC, AGA-negative or EGFR activating mutation, any PD-L1. DLs used will be determined by the IRC based on data generated from Part 1 and Part 2a.
Part 2b (Cohort D1, Arm 1) - BNT326 + pumitamigEXPERIMENTALCombination therapy of BNT326 and pumitamig. In participants with 1L, squamous or non-squamous NSCLC, AGA-negative, PD-L1 ≥50%. DLs used will be determined by the IRC based on data generated from Part 1 and Part 2a.
Part 2b (Cohort D1, Arm 2) - BNT326 + pumitamigEXPERIMENTALCombination therapy of BNT326 and pumitamig. In participants with 1L, squamous or non-squamous NSCLC, AGA-negative, PD-L1 ≥50%. DLs used will be determined by the IRC based on data generated from Part 1 and Part 2a.
Part 2b (Cohort D1, Arm 3) - Pumitamig monotherapyEXPERIMENTALPumitamig monotherapy. In participants with 1L, squamous or non-squamous NSCLC, AGA-negative, PD-L1 ≥50%. DL used will be determined by the IRC based on data generated from Part 1 and Part 2a.
Part 2b (Cohort D2, Arm 1) - BNT326 + pumitamigEXPERIMENTALCombination therapy of BNT326 and pumitamig. In participants with 1L, squamous or non-squamous NSCLC, AGA-negative, PD-L1 \<50%. DLs used will be determined by the IRC based on data generated from Part 1 and Part 2a.
Part 2b (Cohort D2, Arm 2) - BNT326 + pumitamigEXPERIMENTALCombination therapy of BNT326 and pumitamig. In participants with 1L, squamous or non-squamous NSCLC, AGA-negative, PD-L1 \<50%. DLs used will be determined by the IRC based on data generated from Part 1 and Part 2a.
Part 1 (Cohort 1A) - BNT326 monotherapyEXPERIMENTALBNT326 (DL1 or DL2 or DL3) in participants with cutaneous melanoma 2L+
Part 1 (Cohort 1B) - BNT326 monotherapyEXPERIMENTALBNT326 (DL1 or DL2) in participants with NSCLC 2L+ AGA-negative
Part 1 (Cohort 1C) - BNT326 monotherapyEXPERIMENTALBNT326 (DL1 or DL2) in participants with NSCLC 2L+ EGFRm
Part 1 (Cohort 1D) - BNT326 monotherapyEXPERIMENTALBNT326 (DL2 or DL3) in participants with rare melanoma 2L+
Part 1 (Cohort 1E) - BNT326 monotherapyEXPERIMENTALBNT326 (DL2) in participants with advanced solid tumors 2L+
Part 1 (Cohort 1F, DDI) - BNT326 + itraconazoleEXPERIMENTALBNT326 (DL1 or DL2 or DL3) + itraconazole in participants with advanced solid tumors
Part 1 (Cohort 1F, DDI) - BNT326 + paroxetineEXPERIMENTALBNT326 (DL1 or DL2 or DL3) + paroxetine in participants with advanced solid tumors
Part 1 (Cohort 1G) - BNT326 monotherapyEXPERIMENTALBNT326 (DL2 or DL3) in participants with cervical cancer 2L+
Part 2 (Cohort 2A dose escalation) - BNT326 + pumitamigEXPERIMENTALCombination therapy of BNT326 (DL1 or DL2 or DL3) + pumitamig (DL1 or DL2) in participants with cutaneous melanoma 2L+. Optionally, combinations with lower doses of BNT326 and/or pumitamig may be explored.
Part 2 (Cohort 2A dose randomization/expansion) - BNT326 + pumitamigEXPERIMENTALCombination therapy of BNT326 (DL1 or DL2 or DL3) + pumitamig (DL3 or DL4 or DL 5) in participants with cutaneous melanoma 2L+. Optionally, combinations with lower doses of BNT326 and/or pumitamig may be explored.
Part 2 (Cohort 2B dose escalation) - BNT326 + pumitamigEXPERIMENTALCombination therapy of BNT326 (DL1 or DL2 or DL3) + pumitamig (DL1 or DL2) in participants with HER2-negative breast cancer (triple-negative breast cancer and hormone receptor-positive /HER2-negative breast cancer) 2L+/1L
Part 2 (Cohort 2B dose randomization/expansion) - BNT326 + pumitamigEXPERIMENTALCombination therapy of BNT326 (DL1 or DL2 or DL3) + pumitamig (DL3 or DL4 or DL 5) in participants with HER2-negative breast cancer (triple-negative breast cancer and hormone receptor-positive /HER2-negative breast cancer) 2L+/1L
Part 2 (Cohort 2C) - Optional - BNT326 + pumitamigEXPERIMENTALCombination therapy of BNT326 + pumitamig in participants with cutaneous melanoma 1L+
Part 2 (Cohort 2D1) - BNT326 monotherapyEXPERIMENTALBNT326 (DL2) in participants with GC/GEJC 2L+
Part 2 (Cohort 2D2) - BNT326 + pumitamigEXPERIMENTALCombination therapy of BNT326 (DL2 or DL3) + pumitamig (DL1 or DL2) in participants with GC/GEJC 2L+
Part 2 (Cohort 2E1) - BNT326 monotherapyEXPERIMENTALBNT326 (DL2) in participants with colorectal cancer 2L+
Part 2 (Cohort 2E2) - BNT326 + pumitamigEXPERIMENTALCombination therapy of BNT326 (DL2 or DL3) + pumitamig (DL1 or DL2) in participants with colorectal cancer 2L+
Part 2 (Cohort 2F) - BNT326 + pumitamigEXPERIMENTALCombination therapy of BNT326 with pumitamig in participants with cervical cancer 2L+ (BNT326 DL2 with pumitamig DL1 or DL2 or BNT326 DL3 with pumitamig DL1 or DL2)

Interventions

NameTypeDescription
BNT326DRUGintravenous (IV) infusion
PumitamigDRUGIV infusion
ItraconazoleDRUGOral administration
ParoxetineDRUGOral administration
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites85

Key Inclusion Criteria (applicable to all participants and all parts unless otherwise specified): * Aged ≥18 years at the time of giving informed consent. Local laws will be followed if the age of consent is older. * Have measurable disease defined by RECIST v1.1. * Have Eastern Cooperative Oncolog...

Countries:United StatesAustraliaChinaGermanyItalyMoldovaPolandSpainTurkey (Türkiye)United KingdomBelgium
Unlock Eligibility Criteria

Competitive Landscape -Other Solid Tumors 9 trials (matched to "Advanced Solid Tumor")

Recent Changes (Last 90 Days)

LOWSep 2, 2026NCT07070232lastUpdatePostDate: changed
LOWSep 2, 2026NCT07070232lastUpdatePostDate: changed
LOWSep 2, 2026NCT07070232lastUpdatePostDate: changed
MEDIUMAug 5, 2026NCT07111520Enrollment: 420 → 880
MEDIUMJul 22, 2026NCT07070232Enrollment: 980 → 1438
MEDIUMJul 22, 2026NCT07070232Enrollment: 980 → 1438

Frequently asked questions about BNT326

What is BNT326 used for?

BNT326 is an investigational small molecule being studied for the treatment of advanced solid tumors and non-small cell lung cancer (NSCLC). It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.

What does BNT326 target?

BNT326 targets HER3, a protein involved in tumor growth. By targeting HER3, the drug aims to interfere with cancer cell signaling. It is being evaluated alone and in combination with other investigational treatments in clinical trials.

Who is developing BNT326?

BNT326 is being developed by BioNTech SE, a biotechnology company traded on the NASDAQ under the ticker symbol BNTX. The company is conducting Phase 1 clinical trials to assess the safety and potential benefit of the drug.

What phase is BNT326 in?

BNT326 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by the FDA or other regulatory agencies. The ongoing trials are designed to evaluate safety, tolerability, and preliminary efficacy.

What clinical trials is BNT326 in?

BNT326 is being studied in two Phase 1 trials. NCT07070232 evaluates BNT326 alone or with BNT327 in advanced solid tumors, enrolling 1,438 participants. NCT07111520 tests BNT326 with BNT327 in non-small cell lung cancer, enrolling 880 participants. Both are recruiting.

Is BNT326 the same as BNT327?

No, BNT326 and BNT327 are different investigational drugs. BNT326 is the subject of study, while BNT327 is another investigational treatment used in combination with BNT326 in clinical trials for advanced solid tumors and non-small cell lung cancer.